Referencias bibliográficas

1. Jarius S, Wildemann B. Devic's disease before Devic: On the contribution of Friedrich Albin Schanz (1863-1923). J Neurol Sci. 2017 Aug 15;379:99-102. [Pubmed]
2. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004 Dec 11-17;364(9451):2106-12. doi: 10.1016/S0140-6736(04)17551-X. [Pubmed]
3. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 May 23;66(10):1485-9. [Pubmed]
4. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007 Sep;6(9):805-15. [Pubmed]
5. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al.; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. [Pubmed]
6. Höftberger R, Sepulveda M, Armangue T, Blanco Y, Rostásy K, Calvo AC, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. 2015 Jun;21(7):866-74. [Pubmed]
7. Sepúlveda M, Armangué T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, et al. Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm. 2016 Apr 14;3(3):e225. [Pubmed]
8. Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, Kleiter I, Chitnis T; GJCF International Clinical Consortium & Biorepository for Neuromyelitis Optica. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler. 2015 Jun;21(7):845-53. [Pubmed]
9. Sepúlveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, et al. Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Mult Scler. 2018 Dec;24(14):1843-51. [Pubmed]
10. Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016 May;79(5):775-83. [Pubmed]
11. Jacob A, Panicker J, Lythgoe D, Elsone L, Mutch K, Wilson M, et al. The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol. 2013 Aug;260(8):2134-7. [Pubmed]
12. Cossburn M, Tackley G, Baker K, Ingram G, Burtonwood M, Malik G, et al. The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol. 2012 Apr;19(4):655-9. [Pubmed]
13. Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, et al. Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-8. [Pubmed]
14. Papp V, Illes Z, Magyari M, Koch-Henriksen N, Kant M, Pfleger CC, et al. Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology. 2018 Dec 11;91(24):e2265-e2275. [Pubmed]
15. Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011 May 3;76(18):1589-95. [Pubmed]
16. Blanco Y, Ercilla-González G, Llufriu S, Casanova-Estruch B, Magraner MJ, Ramió-Torrentá L, et al. [HLA-DRB1 typing in Caucasians patients with neuromyelitis optica]. Rev Neurol. 2011 Aug 1;53(3):146-52. Spanish. [Pubmed]
17. Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, et al.; GJCF-ICC&BR. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler. 2015 May;21(6):678-88. [Pubmed]
18. Martínez-Lapiscina EH, Sepúlveda M, Torres-Torres R, Alba-Arbalat S, Llufriu S, Blanco Y, et al. Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2016 Sep;9(5):436-40. [Pubmed]
19. Kaufhold F, Zimmermann H, Schneider E, Ruprecht K, Paul F, Oberwahrenbrock T, Brandt AU. Optic neuritis is associated with inner nuclear layer thickening and microcystic macular edema independently of multiple sclerosis. PLoS One. 2013 Aug 6;8(8):e71145. Erratum in: PLoS One. 2013;8(10). [Pubmed]
20. Usmani N, Bedi G, Lam BL, Sheremata WA. Association between paroxysmal tonic spasms and neuromyelitis optica. Arch Neurol. 2012 Jan;69(1):121-4. [Pubmed]
21. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005 Nov 8;65(9):1479-82. [Pubmed]
22. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Clinical spectrum of CNS aquaporin-4 autoimmunity. Neurology. 2012 Apr 10;78(15):1179-85. [Pubmed]
23. Popescu BF, Lennon VA, Parisi JE, Howe CL, Weigand SD, Cabrera-Gómez JA, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology. 2011 Apr 5;76(14):1229-37. [Pubmed]
24. Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler. 2014 Jun;20(7):843-7. [Pubmed]
25. Kravljanac R, Martinović V, Dujmović I, Djurić M, Kuzmanović M, Weinshenker BG, Drulović J. Relapsing inappropriate antidiuretic hormone secretion in an anti-aquaporin-4 antibody positive paediatric patient. Mult Scler. 2014 Sep;20(10):1404-6. [Pubmed]
26. Okuma H, Matsumura K, Hatanaka Y, Saito F, Sonoo M. Sudden onset of sleep due to hypothalamic lesions in neuromyelitis optica spectrum disorder positive for anti-aquaporin-4 antibody. Mult Scler. 2014 Sep;20(10):1407-8. [Pubmed]
27. Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, et al.; Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015 Mar 17;84(11):1165-73. [Pubmed]
28. Sepúlveda M, Sola-Valls N, Escudero D, Rojc B, Barón M, Hernández-Echebarría L, et al. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. Mult Scler. 2018 Nov;24(13):1753-9. [Pubmed]
29. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006 Mar;63(3):390-6. [Pubmed]
30. Akaishi T, Nakashima I, Takeshita T, Kaneko K, Mugikura S, Sato DK, et al. Different etiologies and prognoses of optic neuritis in demyelinating diseases. J Neuroimmunol. 2016 Oct 15;299:152-7. [Pubmed]
31. Cassinotto C, Deramond H, Olindo S, Aveillan M, Smadja D, Cabre P. MRI of the spinal cord in neuromyelitis optica and recurrent longitudinal extensive myelitis. J Neuroradiol. 2009 Oct;36(4):199-205. [Pubmed]
32. Wang H, Wang C, Qiu W, Lu Z, Hu X, Wang K. Cerebrospinal fluid light and heavy neurofilaments in neuromyelitis optica. Neurochem Int. 2013 Dec;63(8):805-8. [Pubmed]
33. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999 Sep 22;53(5):1107-14. [Pubmed]
34. Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F; Spanish-Italian NMO Study Group. Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol. 2007 Sep;254(9):1233-7. [Pubmed]
35. Hamid SH, Elsone L, Mutch K, Solomon T, Jacob A. The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates. Mult Scler. 2017 Feb;23(2):228-33. [Pubmed]
36. Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012 Jun;135(Pt 6):1834-49. [Pubmed]
37. Collongues N, Marignier R, Zéphir H, Papeix C, Blanc F, Ritleng C, et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology. 2010 Mar 2;74(9):736-42. [Pubmed]
38. Palace J, Lin DY, Zeng D, Majed M, Elsone L, Hamid S, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain. 2019 May 1;142(5):1310-23. [Pubmed]
39. Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek AM, Smith CY, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013 Oct 1;81(14):1197-204. [Pubmed]
40. Sepúlveda M, Delgado-García G, Blanco Y, Sola-Valls N, Martínez-Lapiscina EH, Armangué T, et al. Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus. Neurol Neuroimmunol Neuroinflamm. 2019 Aug 30;6(6):e607. [Pubmed]
41. Costello F. Neuromyelitis Optica Spectrum Disorders. Continuum (Minneap Minn). 2022 Aug 1;28(4):1131-70. Erratum in: Continuum (Minneap Minn). 2022 Dec 1;28(6):1859. [Pubmed]
42. Wingerchuk DM, Lucchinetti CF. Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2022 Aug 18;387(7):631-9. [Pubmed]